Sermorelin Protocol

Dosing & Research

Last Updated: September 4, 2026

Chemical Identity

Molecular Formula: C149H246N44O42S
Molecular Weight: 3357.93 g/mol
CAS Number: 86168-78-7

GH deficiency testing/support, IGF-1 axis modulation, Body-composition research, Recovery and sleep studies

Evidence Level

Human Clinical Data Available

Species Studied

Human • Rat

Half-Life

Approximately 10-20 minutes

Administration

Subcutaneous

Frequency

Once Daily, 2 Hours After Last Meal

How It Works

GH deficiency testing/support
IGF-1 axis modulation
Body-composition research
Recovery and sleep studies

Dosing Structure

Dose

200–250 mcg

Frequency

Once Daily, 2 Hours After Last Meal

Notes

1x Daily: 200–500mcg taken 2 hours after last meal (once daily). IM is also effective. Inject: Lower abdomen, anterior thigh, posterior upper arm (rotate). Administer at least 2 hours after last meal. Break: 1-2 months or 5 days on/2 days off.

Example Protocols

Dose: 200–250 mcg

Frequency: Once Daily, 2 Hours After Last Meal

Duration: 6-12 weeks

Off Period: Not listed

Calculate dosing →

Find Research Grade Sermorelin

Recommended vendors for sourcing research-grade material. PeptaBase does not sell peptides directly.

Vendor One Research Labs

COA Verified

Third-party COA-verified research peptides with published batch testing.

Source Coming Soon

Vendor Two Sciences

Purity Tested

US-based research compound supplier with independent purity testing.

Source Coming Soon

Vendor Three Peptide Co.

Bulk research peptide sourcing with batch-level documentation.

Source Coming Soon

View all recommended vendors →

Protocol Notes

•

1x Daily: 200–500mcg taken 2 hours after last meal (once daily).

•

IM is also effective.

•

Inject: Lower abdomen, anterior thigh, posterior upper arm (rotate).

•

Administer at least 2 hours after last meal.

•

Break: 1-2 months or 5 days on/2 days off.

What Is Sermorelin?

Sermorelin (GHRH 1-29 NH₂) is the first 29 amino acids of endogenous growth hormone-releasing hormone, the minimal active fragment required to stimulate GH secretion from the pituitary. It is FDA-approved for the diagnosis of GH deficiency in children and has been studied for adult hormone optimization, age-related GH decline, and as a gentler alternative to direct GH injection.

Research Observations - Not Medical Claims

▸GH deficiency diagnosis: FDA-approved sermorelin stimulation test reliably differentiates hypothalamic from pituitary GH deficiency, with high sensitivity in pediatric populations (PMID: 1987230).
▸Adult GH restoration: Six-month sermorelin administration in GH-deficient adults restored IGF-1 to normal range and improved body composition (lean mass +3.1 kg, fat mass −2.4 kg) in open-label trials.
▸Sleep quality: Sermorelin given at bedtime in older adults with low GH amplified slow-wave sleep GH pulses - the primary physiological GH secretion window (PMID: 7768356).
▸Short half-life: Sermorelin has a ~10–20 min half-life - much shorter than CJC-1295 with DAC - requiring 3× daily or bedtime-only administration protocols.
▸Safety profile: In children's diagnostic use and adult GH optimization trials, sermorelin shows a markedly more favorable safety profile than direct GH administration, with no reports of supraphysiological IGF-1 spikes at standard doses.

Evidence Summary

Human Clinical Data AvailableFDA Approved (diagnostic use, pediatric GH deficiency) - Compounded for off-label adult use; not commercially available in US

Evidence StrengthModerate